Clinical Study Of Treating Metastasis Breast Cancer(MBC) With Difference Dose Of Paclitaxel

Breast cancer is the most common disease among women, and its morbidity is going up increasingly. Chemotherapy plays an important role in the treatment, either adjuvant or rescue setting, of this disease. Paclitaxel is highly active agents against breast cancer. By binding to the β subunit of tubulin, paclitaxel can stabilize and promote the reorganization of the microtubules in tumor cell, making it accumulated in G2/M phase and ultimately cause cell death. Paclitaxel is the most sold anti—tumors agent in latest years, one of most important drug for MBC . Now the natural resources of paclitaxel is seldom to be find and cannot be man made . Researching the more regulation and efficacy for clinical us is important.objective To evaluate the relationship of dose intensity and the efficacy and toxicity of taxanes as a single agent in metastasis breast cancer(MBC). Methods From Octomber 2002 to February 2005, there were 36 cases of metastasis breast cancer patients received chemotherapy with paclitaxel used as a single agent, expression different clinical significance . Results As a single agent, the response rates of paclitaxel was 41.7%, the response rate of this agent in soft tissue metastatic patients was 36.0%, it is highly effective in lung metastatic patients with a RR of 53.8%, whereas the was only 9.1% in liver metastatic patients; The relative dose intensity in the whole group is among 0.57—1.2, according to the relative dose intensity of paclitaxel used, all the patients were grouped into three categories( ≥1, ≥ 0 .9 ,...